secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2023-12-18T23:59:59+00:00
Accession:  0001787306-23-000132
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Arcutis' ZORYVE foam for seborrheic dermatitis in ages 9+
----------------------------------------------------------------------

- ZORYVE (roflumilast) topical foam 0.3% approved by FDA for seborrheic dermatitis.
- Indicated for individuals 9 years of age and older.
- Prior FDA approval exists for ZORYVE cream 0.3% for plaque psoriasis (ages 6+).
- Approval expands Arcutis' commercial product portfolio into a new dermatology indication.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730623000132/0001787306-23-000132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730623000132/arqt-20231215.htm
  HTML page:      https://secwatch.observer/filing/0001787306-23-000132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer